FindTrial
Sign In

cliniMACs HUD for T Cell Depletion

cliniMACs HUD for T Cell Depletion

Status
NO_LONGER_AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT02915406
Enrollment
Unknown
Registered
2016-09-27
Start date
Unknown
Completion date
Unknown
Last updated
2017-08-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

x Linked Combined Immunodeficiency

Brief summary

This protocol is designed to enable access to related or unrelated CD34 cells manufactured using the CliniMACS (Miltenyi) under the HUD designation for patients needing T cell depleted allogeneic grafts for hematopoietic stem cell transplant (HSCT). This will include patients with inherited immunodeficiency disorders as well as patients with malignancies, bone marrow failure, and other rare diseases amenable to HSCT. Finally, patients with poor graft function and Graft Versus Host Disease(GVHD) after a previous HSCT may require a boost of T-cell depleted donor Peripheral Blood Stem Cell (PBSCs) or bone marrow cells that are CD34 selected using the CliniMACS device ENROLLMENT BY INVITATION ONLY

Interventions

DEVICECliniMACs

Sponsors

Jackson Health System
CollaboratorOTHER
University of Miami
Lead SponsorOTHER

Eligibility

Sex/Gender
ALL
Age
No minimum to 65 Years

Inclusion criteria

severe combined immune deficiency need for stem cell boost

Exclusion criteria

n/a

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026